This company has been moved to the archive! The financial data has not been updated since May 7, 2020.
Cash Flow Statement
The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.
The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.
Allergan PLC, consolidated cash flow statement
US$ in thousands
12 months ended:
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Net income (loss)
(5,265,100)
(5,086,200)
(4,118,900)
14,979,500)
3,919,400)
Depreciation
204,500)
196,300)
171,500)
155,800)
218,300)
Amortization
5,856,600)
6,552,300)
7,197,100)
6,475,200)
5,777,000)
Provision for inventory reserve
160,200)
96,400)
102,200)
181,400)
140,900)
Share-based compensation
214,300)
239,800)
293,300)
334,500)
690,400)
Deferred income tax benefit
(660,900)
(1,255,700)
(7,783,100)
(1,443,900)
(7,380,100)
Pre-tax gain on sale of businesses to Teva
—)
—)
—)
(24,511,100)
—)
Non-cash tax effect of gain on sale of businesses to Teva
—)
—)
—)
5,285,200)
—)
Goodwill impairments
3,552,800)
2,841,100)
—)
—)
—)
In-process research and development impairments
436,000)
804,600)
1,452,300)
743,900)
511,600)
Loss on asset sales and impairments, net
440,200)
2,857,600)
3,927,700)
5,000)
334,400)
Net income impact of other-than-temporary loss on investment in Teva securities
—)
—)
3,273,500)
—)
—)
Charge to settle Teva related matters
—)
—)
387,400)
—)
—)
Loss on forward sale of Teva shares
—)
—)
62,900)
—)
—)
Gain on sale of Teva securities, net
—)
(60,900)
—)
—)
—)
Amortization of inventory step-up
—)
—)
131,700)
42,400)
1,192,900)
Gain on sale of businesses
—)
(182,600)
—)
—)
—)
Non-cash extinguishment of debt
200)
30,000)
(15,700)
—)
—)
Cash discount related to extinguishment of debt
—)
(45,600)
—)
—)
—)
Amortization of deferred financing costs
17,500)
22,600)
27,800)
51,000)
298,300)
Amortization of right of use assets
130,900)
—)
—)
—)
—)
Contingent consideration adjustments, including accretion
54,100)
(106,500)
(133,200)
(66,800)
108,800)
Excess tax benefit from stock-based compensation
—)
—)
—)
(20,400)
(76,100)
Other, net
(5,500)
29,000)
(37,000)
(59,900)
66,400)
(Increase) decrease in accounts receivable, net
(358,800)
(37,000)
(188,300)
(191,000)
(1,034,300)
(Increase) decrease in inventories
(393,400)
(145,700)
(144,800)
(268,400)
(226,200)
(Increase) decrease in prepaid expenses and other current assets
(78,100)
4,300)
27,900)
29,900)
70,900)
Increase (decrease) in accounts payable and accrued expenses
1,434,400)
151,600)
95,900)
313,500)
142,500)
Increase (decrease) in income and other taxes payable
1,697,900)
(1,191,600)
1,114,100)
(326,600)
(87,800)
Increase (decrease) in other assets and liabilities
(199,100)
(73,700)
29,100)
(283,900)
(137,300)
Changes in assets and liabilities, net of effects of acquisitions
2,102,900)
(1,292,100)
933,900)
(726,500)
(1,272,200)
Reconciliation to net cash provided by operating activities
12,503,800)
10,726,300)
9,992,300)
(13,554,200)
610,600)
Net cash provided by operating activities
7,238,700)
5,640,100)
5,873,400)
1,425,300)
4,530,000)
Additions to property, plant and equipment
(375,200)
(253,500)
(349,900)
(331,400)
(454,900)
Additions to product rights and other intangibles
(58,300)
—)
(614,300)
(2,000)
(154,700)
Sale of businesses to Teva
—)
—)
—)
33,804,200)
—)
Additions to investments
(3,938,000)
(2,471,700)
(9,783,800)
(15,743,500)
(24,300)
Proceeds from sale of investments and other assets
1,569,600)
6,259,300)
15,153,300)
7,771,600)
883,000)
Payments to settle Teva related matters
—)
(466,000)
—)
—)
—)
Proceeds from sales of property, plant and equipment
23,700)
30,400)
7,100)
33,300)
140,100)
Acquisitions of businesses, net of cash acquired
(80,600)
—)
(5,290,400)
(1,198,900)
(37,510,100)
Net cash (used in) provided by investing activities
(2,858,800)
3,098,500)
(878,000)
24,333,300)
(37,120,900)
Proceeds from borrowings of long-term indebtedness, including credit facility
11,900)
2,657,000)
3,550,000)
1,050,000)
30,137,700)
Payments on debt, including capital lease obligations and credit facility
(1,044,900)
(8,804,500)
(6,413,600)
(10,848,700)
(5,134,200)
Debt issuance and other financing costs
—)
(10,400)
(20,600)
—)
(310,800)
Proceeds from issuance of preferred shares
—)
—)
—)
—)
4,929,700)
Proceeds from issuance of ordinary shares
—)
—)
—)
—)
4,071,100)
Payments of contingent consideration and other financing
(9,300)
(30,900)
(511,600)
(161,100)
(230,100)
Proceeds from stock plans
91,200)
102,400)
183,400)
172,100)
230,000)
Proceeds from forward sale of Teva securities
—)
465,500)
—)
—)
—)
Payments to settle Teva related matters
—)
(234,000)
—)
—)
—)
Repurchase of ordinary shares
(840,600)
(2,775,400)
(493,000)
(15,076,400)
(118,000)
Dividends paid
(974,400)
(1,049,800)
(1,218,200)
(278,400)
(208,100)
Excess tax benefit from stock-based compensation
—)
—)
—)
20,400)
76,100)
Net cash provided by (used in) financing activities
(2,766,100)
(9,680,100)
(4,923,600)
(25,122,100)
33,443,400)
Effect of currency exchange rate changes on cash and cash equivalents
9,100)
4,700)
21,400)
(8,500)
(6,500)
Net increase (decrease) in cash and cash equivalents
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Allergan PLC net cash provided by operating activities decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Net cash (used in) provided by investing activities
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Allergan PLC net cash (used in) provided by investing activities increased from 2017 to 2018 but then decreased significantly from 2018 to 2019.
Net cash provided by (used in) financing activities
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Allergan PLC net cash provided by (used in) financing activities decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
